|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>LAMP5</i> was validated as being specifically and highly expressed in patients with MLL leukemia and was associated with a poor outcome.
|
30651276 |
2019 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
MLL rearrangements occurring in leukemia include MLL fusion genes, partial tandem duplications of MLL and MLL amplification.
|
15464450 |
2004 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL fusion proteins associated with human leukemia contain the menin interaction peptide and frequently recruit H3K79 (histone H3 lysine 79) methylation activity.
|
20558618 |
2010 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL1-fusion proteins resulting from chromosomal translocations are molecular hallmarks of a special type of leukemia, which occurs in over 70% infant leukemia patients and often accompanies poor prognosis.
|
21439245 |
2011 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL gene involvement, which has been reported in some leukemia cases, was examined by FISH in fusion partner-unknown cases.
|
23035786 |
2013 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL fusion proteins in leukemia induce aberrant transcriptional elongation and associated chromatin perturbations; however, the upstream signaling pathways and activators that recruit or retain MLL oncoproteins at initiated promoters are unknown.
|
24054986 |
2013 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
KMT2A (MLL) rearrangements are observed in various types of pediatric and adult leukemia, but only one adult case report has so far showed KMT2A (MLL)-MLLT1 gene rearrangements in BPDCN.
|
26164398 |
2015 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children.
|
7756657 |
1995 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children.
|
9703001 |
1998 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A hematological cancer panel assay indicated that EZH1/2 dual inhibitor has efficacy against some lymphomas, multiple myeloma, and leukemia with fusion genes such as MLL-AF9, MLL-AF4, and AML1-ETO.
|
28741798 |
2017 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A much rarer subgroup of patients with <i>MLL1</i> rearrangements develop leukemia that is attributable to prior treatment with certain chemotherapeutic agents-so-called therapy-related leukemias.
|
28232907 |
2017 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A pediatric B lineage leukemia with coincident MYC and MLL translocations.
|
20829716 |
2011 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A relevant role of septins in leukemogenesis has been uncovered by their involvement as fusion partners in MLL-related leukemia.
|
19445675 |
2009 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A role for MEIS1 in MLL-fusion gene leukemia.
|
19109563 |
2009 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A strong DNase I hypersensitive site (HS) also mapped near exon 9 in four leukemia cell lines, including two in which MLL was rearranged [a t(6;11) and a t(9;11)], and in two lymphoblastoid cell lines with normal MLL.
|
9808573 |
1998 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 760 MLL-rearranged biopsy samples obtained from 384 pediatric and 376 adult leukemia patients were characterized at the molecular level.
|
19262598 |
2009 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia.
|
26837759 |
2016 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
AF10 is a transcription factor that has been implicated in the development of leukemia following chromosomal rearrangements between the AF10 gene and one of at least two other genes, MLL and CALM.
|
23284727 |
2012 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
ALOX5 exhibits anti-tumor and drug-sensitizing effects in MLL-rearranged leukemia.
|
28500307 |
2017 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although TET1 was first identified as a fusion partner of the mixed lineage leukemia (MLL) gene in acute myeloid leukemia carrying t(10,11), its definitive role in leukemia is unclear.
|
23818607 |
2013 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Among the three age groups, older patients more often had higher risk ALL due to T-ALL (32%/25%/9%, P<0.001), KMT2A rearrangements (6%/5%/3%, P<0.001) and higher day 29 residual leukemia for B-lineage (P<0.001), but not T-ALL (P=0.53).
|
28819280 |
2018 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands.
|
23014531 |
2012 |
|
Childhood Leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
ARID5B polymorphism confers an increased risk to acquire specific MLL rearrangements in early childhood leukemia.
|
24564228 |
2014 |
|
Childhood Leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
As an example of the development of new therapeutics for rare indications, I describe here the drug discovery efforts leading to the development of DOT1L inhibitors for the treatment of MLL-rearranged leukemia.
|
24319157 |
2013 |
|
Childhood Leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As dysregulated homeobox gene expression is also a feature of MLL-rearranged leukemia, the gene expression signatures of NPM1-mutated and MLL-rearranged leukemias were compared.
|
17597811 |
2007 |